Clearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking Research
Clearmind Medicine Inc. (Nasdaq: CMND) successfully participated in the Psychedelic Medicine – Israel 2024 conference in Tel Aviv. CEO Adi Zuloff-Shani presented on '5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator', highlighting its potential in treating addiction-related disorders. Researchers from The Hebrew University of Jerusalem also presented an abstract on MEAI's ability to attenuate diet-induced obesity and related metabolic complications.
The conference provided Clearmind an opportunity to showcase its innovative therapies, engage with industry leaders, and expand its network of partners. Dr. Zuloff-Shani noted that the MEAI research garnered significant interest and acceptance among event participants, reinforcing Clearmind's position in the psychedelic-derived therapeutics field.
Clearmind Medicine Inc. (Nasdaq: CMND) ha partecipato con successo alla conferenza Psychedelic Medicine – Israele 2024 a Tel Aviv. Il CEO Adi Zuloff-Shani ha presentato '5-Metossido-2-Amminoindano (MEAI) come regolatore del comportamento da binge', evidenziando il suo potenziale nel trattamento dei disturbi legati all'addiction. I ricercatori dell'Università Ebraica di Gerusalemme hanno anche presentato un abstract sulla capacità del MEAI di attenuare l'obesità indotta dalla dieta e le complicazioni metaboliche correlate.
La conferenza ha fornito a Clearmind l'opportunità di mostrare le sue terapie innovative, interagire con leader del settore ed espandere la sua rete di partner. Dr. Zuloff-Shani ha notato che la ricerca sul MEAI ha suscitato un interesse significativo e accettazione tra i partecipanti all'evento, rafforzando la posizione di Clearmind nel campo delle terapie derivate da sostanze psichedeliche.
Clearmind Medicine Inc. (Nasdaq: CMND) participó con éxito en la conferencia de Medicina Psicodélica – Israel 2024 en Tel Aviv. El CEO Adi Zuloff-Shani presentó sobre '5-Metoxi-2-Aminoindano (MEAI) como regulador del comportamiento de atracón', destacando su potencial en el tratamiento de trastornos relacionados con la adicción. Investigadores de la Universidad Hebrea de Jerusalén también presentaron un resumen sobre la capacidad del MEAI para atenuar la obesidad inducida por la dieta y las complicaciones metabólicas relacionadas.
La conferencia ofreció a Clearmind la oportunidad de presentar sus terapias innovadoras, interactuar con líderes de la industria y expandir su red de socios. El Dr. Zuloff-Shani señaló que la investigación sobre el MEAI generó un interés y aceptación significativos entre los participantes del evento, reforzando la posición de Clearmind en el campo de las terapias derivadas de psicodélicos.
Clearmind Medicine Inc. (Nasdaq: CMND)는 텔아비브에서 열린 환각제 의학 - 이스라엘 2024 컨퍼런스에 성공적으로 참여했습니다. CEO Adi Zuloff-Shani는 '5-메톡시-2-아미노인단 (MEAI)을 폭식 행동 조절제로서 발표하며, 중독 관련 질환 치료에서의 잠재력을 강조했습니다. 예루살렘 히브리 대학교의 연구자들도 MEAI가 식이 유도 비만 및 관련 대사 합병증을 완화하는 능력에 대한 초록을 발표했습니다.
이번 컨퍼런스는 Clearmind에게 혁신적인 치료법을 선보이고, 업계 리더와 교류하며, 파트너 네트워크를 확장할 수 있는 기회를 제공했습니다. Zuloff-Shani 박사는 MEAI 연구가 이벤트 참가자들 사이에서 상당한 관심과 수용을 받았으며, Clearmind의 환각제 유래 치료제 분야에서의 입지를 강화하는 데 도움이 되었다고 언급했습니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a participé avec succès à la conférence Médecine Psychédélique – Israël 2024 à Tel Aviv. Le PDG Adi Zuloff-Shani a présenté '5-Méthoxy-2-Aminoindane (MEAI) en tant que régulateur du comportement alimentaire compulsif', mettant en avant son potentiel dans le traitement des troubles liés à l'addiction. Des chercheurs de l'Université Hébraïque de Jérusalem ont également présenté un résumé sur la capacité du MEAI à atténuer l'obésité induite par l'alimentation et les complications métaboliques associées.
La conférence a offert à Clearmind l'opportunité de présenter ses thérapies innovantes, d'échanger avec des leaders de l'industrie et d'élargir son réseau de partenaires. Le Dr Zuloff-Shani a souligné que la recherche sur le MEAI a suscité un intérêt et une acceptation considérables parmi les participants à l'événement, renforçant la position de Clearmind dans le domaine des thérapies dérivées des psychédéliques.
Clearmind Medicine Inc. (Nasdaq: CMND) hat erfolgreich an der Konferenz für Psychedelische Medizin – Israel 2024 in Tel Aviv teilgenommen. CEO Adi Zuloff-Shani präsentierte über '5-Methoxy-2-Aminoindan (MEAI) als Regulator des Binge-Verhaltens', wobei er dessen Potenzial zur Behandlung von suchtbezogenen Störungen hervorhob. Forscher der Hebräischen Universität Jerusalem präsentierten ebenfalls eine Zusammenfassung zur Fähigkeit von MEAI, durch die Ernährung induzierte Fettleibigkeit und damit verbundene metabolische Komplikationen zu verringern.
Die Konferenz bot Clearmind die Möglichkeit, ihre innovativen Therapien vorzustellen, sich mit Branchenführern auszutauschen und ihr Partnernetzwerk zu erweitern. Dr. Zuloff-Shani bemerkte, dass die MEAI-Forschung bei den Teilnehmern der Veranstaltung auf erhebliches Interesse und Akzeptanz stieß, was Clearminds Position im Bereich der psychedelisch abgeleiteten Therapien stärkt.
- Successful presentation of MEAI research at a major psychedelic medicine conference
- Positive reception of MEAI's potential in treating addiction-related disorders and obesity
- Opportunity to engage with industry leaders and expand partner network
- Increased awareness of Clearmind's innovative therapies among global organizations
- None.
Vancouver, Canada, July 31, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today concluded its successful participation at the Psychedelic Medicine – Israel 2024 conference. The event took place in Tel Aviv, Israel, bringing together leading experts and researchers from around the world in the field of psychedelic medicine.
Clearmind’s CEO, Adi Zuloff-Shani, Ph.D., presented a compelling talk titled “5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator.” Dr. Zuloff-Shani provided insights into MEAI’s potential to regulate binge behaviors, highlighting its innovative application in treating addiction-related disorders.
Additionally, esteemed researchers Prof. Joseph Tam and Dr. Saja Baraghithy from the Obesity and Metabolism Laboratory at The Hebrew University of Jerusalem presented their abstract titled “5-methoxy-2-aminoindane (MEAI), a mild psychedelic agent, attenuates diet-induced obesity.” Their presentation delved into the promising results of MEAI in attenuating obesity and its related metabolic complications, showcasing its potential as a therapeutic agent in obesity management.
Dr. Zuloff-Shani, CEO of Clearmind Medicine, commented, "We are honored to be invited to present our groundbreaking research at the Psychedelic Medicine – Israel 2024 conference. One of our goals is to continue to raise awareness of our innovative therapies among global organizations, engaging with industry leaders, establishing our presence, and creating a broad network of partners. The MEAI research gained a high level of interest and was well accepted by the event’s participants. Our dedication to groundbreaking research in psychedelic-derived therapeutics propels us forward as we strive to tackle significant health challenges and garner support from the global psychedelic industry."
About the Presentations:
5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator
Dr. Zuloff-Shani discussed the unique properties of MEAI, a psychoactive aminoindane derivative. MEAI has shown promise in reducing the desire to consume alcoholic beverages while inducing a euphoric, alcohol-like slightly tipsy, but controlled experience. This presentation explored MEAI’s potential as a regulator of binge behaviors, potentially providing a novel approach to addiction treatment.
5-methoxy-2-Aminoindane (MEAI), a Mild Psychedelic Agent, Attenuates Diet-induced Obesity
Dr. Baraghithy presented her research findings on the weight loss effects of MEAI. The study demonstrated that MEAI significantly reduces overweight and adiposity in a diet-induced obesity (DIO) mouse model. The researchers shared compelling evidence that MEAI reduces fat mass, preserves lean mass, improves glucose metabolism, reduces hepatic steatosis and increases energy expenditure, making it a promising therapeutic candidate for obesity management.
Psychedelic Medicine – Israel 2024 provided an interdisciplinary international forum for exchanging ideas, unveiling innovations and training in the basics of psychedelic assisted psychotherapy. The conference encompassed basic, translational and clinical research. A richly varied program included plenary lectures, thematic symposia, poster sessions, workshops and informal salons for discussion and interaction.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of eighteen patent families including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its goal to continue increasing awareness for its innovative therapies among global organizations, in order to engage with industry leaders and establishing its presence, creating wide network of partners and how its commitment to pioneering research in psychedelic-derived therapeutics continues to drive it forward as it seeks to address major health challenges and harness the support of the global industry. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What did Clearmind Medicine (CMND) present at the Psychedelic Medicine – Israel 2024 conference?
How was Clearmind Medicine's (CMND) research received at the Psychedelic Medicine – Israel 2024 conference?
What are the potential applications of MEAI being researched by Clearmind Medicine (CMND)?
Who presented Clearmind Medicine's (CMND) research at the Psychedelic Medicine – Israel 2024 conference?
